35,396 Shares in Ingevity Co. (NYSE:NGVT) Bought by Keeley Teton Advisors LLC

Keeley Teton Advisors LLC bought a new stake in shares of Ingevity Co. (NYSE:NGVT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 35,396 shares of the company's stock, valued at approximately $1,442,000. Keeley Teton Advisors LLC owned approximately 0.10% of Ingevity as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. boosted its position in shares of Ingevity by 37.7% during the 4th quarter. American Century Companies Inc. now owns 1,457,365 shares of the company's stock valued at $59,388,000 after purchasing an additional 398,800 shares in the last quarter. Royce & Associates LP boosted its holdings in Ingevity by 22.4% during the fourth quarter. Royce & Associates LP now owns 1,142,598 shares of the company's stock worth $46,561,000 after buying an additional 208,921 shares in the last quarter. State Street Corp grew its position in Ingevity by 14.7% in the third quarter. State Street Corp now owns 1,546,957 shares of the company's stock worth $60,331,000 after buying an additional 198,300 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Ingevity in the fourth quarter valued at $4,882,000. Finally, Wellington Management Group LLP lifted its position in shares of Ingevity by 5.4% during the 4th quarter. Wellington Management Group LLP now owns 2,239,970 shares of the company's stock valued at $91,279,000 after acquiring an additional 115,581 shares during the last quarter. 91.59% of the stock is owned by institutional investors and hedge funds.

Ingevity Stock Down 3.4 %

Shares of Ingevity stock traded down $1.07 on Monday, hitting $30.51. 20,960 shares of the company traded hands, compared to its average volume of 274,724. The company has a quick ratio of 1.04, a current ratio of 1.87 and a debt-to-equity ratio of 6.86. Ingevity Co. has a 12-month low of $28.49 and a 12-month high of $56.30. The company has a 50-day moving average price of $40.94 and a 200 day moving average price of $41.92. The company has a market cap of $1.11 billion, a PE ratio of -2.58 and a beta of 1.54.

Ingevity (NYSE:NGVT - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.66. The company had revenue of $298.80 million for the quarter, compared to analyst estimates of $297.40 million. Ingevity had a positive return on equity of 41.44% and a negative net margin of 30.60%. Sell-side analysts predict that Ingevity Co. will post 4.45 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on NGVT. Wells Fargo & Company reduced their target price on Ingevity from $45.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. BMO Capital Markets upgraded shares of Ingevity from a "market perform" rating to an "outperform" rating and upped their price target for the company from $62.00 to $65.00 in a research report on Wednesday, February 26th. Finally, StockNews.com cut shares of Ingevity from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.83.

About Ingevity

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.